Figure 2. TLR9 agonist activates pDCs, NKDCs and B cells and increases the release of Th1 and Th2 cytokines in tumor-bearing C57BL/6 mice.

C57BL/6 mice bearing 3LL tumor were divided into 5 groups receiving either PBS, control oligo, TLR9 agonist, RT (20 Gy) or RT+TLR9 agonist. Splenocytes and sera were harvested 24 hours after treatment. The activation of CD8+ T cells, B cells, pDCs and NKDCs was analyzed by flow cytometry (A) and the release of IFN-γ and IL-10 was analyzed by ELISA (B).